Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without image-guided extremely hypofractionated radiotherapy in unresectable/metastatic renal cell carcinoma
jRCTs031180024Phase 2Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of nivolumab in renal cell carcinoma (RCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Response rate of non-irradiated lesion at end of treatment. Started May 2018; status: suspended.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCTs031180024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180024.